```json
{
"content": [
{
"type": "paragraph",
"content": "HER2 antibody-drug conjugates (ADCs) represent a class of precision oncology therapies designed to target HER2-positive cancers, including breast, gastric, and gynecological malignancies. These drugs combine monoclonal antibodies with cytotoxic agents to deliver targeted cell death, minimizing systemic toxicity. The HER2 ADC Drugs market size is projected to expand significantly through 2033, driven by advancements in oncology R&D, rising incidence of HER2-positive cancers, and approval of next-generation ADCs. The industry's growth outlook remains robust, with a forecasted compound annual growth rate (CAGR) exceeding 18% during 2026โ2033."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Enhertu (DS-8201)", "Kadcyla (T-DM1)", "Others"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[1.2, 1.5, 1.9, 2.3, 2.8, 3.2, 3.6, 4.1, 4.6, 5.0, 5.5, 6.0, 6.5], // Enhertu
[0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0], // Kadcyla
[0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5] // Others
]
}
},
{
"type": "paragraph",
"content": "The HER2 ADC Drugs market forecast highlights key macro drivers, including breakthroughs in linker-payload technology and expanding approvals for earlier-stage treatment lines. Regulatory tailwinds, such as FDA Fast Track designations for novel ADCs, are accelerating commercialization. North America dominates the market due to high adoption rates and a strong pipeline, while Asia-Pacific is the fastest-growing region, fueled by rising healthcare expenditure and unmet clinical needs. However, challenges such as high treatment costs and resistance mechanisms may temper industry expansion in the medium term."
}
]
}
```
